Cargando…

Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper

While systemic intravenous thrombolysis decreases mortality in patients with high-risk pulmonary embolism (PE), it clearly increases haemorrhagic risk. There are many contraindications to thrombolysis, and efforts should aim at selecting those patients who will benefit most, without suffering compli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abraham, Paul, Arroyo, Diego A, Giraud, Raphael, Bounameaux, Henri, Bendjelid, Karim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Pulmonary Vascular Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845427/ https://www.ncbi.nlm.nih.gov/pubmed/29531763 http://dx.doi.org/10.1136/openhrt-2017-000735

Ejemplares similares

ACUTE PULMONARY EMBOLISM AND MYOCARDIAL INJURY IN COVID-19 PATIENT
por: Alfaki, Musaab, et al.
Publicado: (2020)

SADDLE PULMONARY EMBOLISM WITH CRITICAL LIMB ISCHEMIA IN COVID-19
por: MAHGOUB, AHMED, et al.
Publicado: (2021)

Continuous long-term heart rate variability and risk assessment in pulmonary hypertension
por: Andersen, Mads Ørbæk, et al.
Publicado: (2023)

MASSIVE PULMONARY EMBOLISM TREATED WITH THROMBOLYSIS IN COVID-19: A CASE SERIES
por: Alarcon-Calderon, Amarilys, et al.
Publicado: (2020)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

DIFFERENCES IN CLINICAL CHARACTERISTICS, TREATMENT, AND OUTCOME OF PULMONARY EMBOLISM ACCORDING TO COVID-19 STATUS
por: KELTY, CATHERINE, et al.
Publicado: (2022)

RIGHT VENTRICULAR PARAMETERS AND OUTCOMES IN PATIENTS WITH DVT AND PULMONARY EMBOLISM ADMITTED WITH COVID-19 INFECTION
por: RODRIGUEZ, BEATRIZ RIVERA, et al.
Publicado: (2022)

THE CLOT THICKENS: DOES THE JOHNSON & JOHNSON COVID-19 VACCINE INCREASE THE RISK OF THROMBUS IN A HYPERCOAGULABLE STATE?
por: RUTENBERG, DAVID, et al.
Publicado: (2021)

PULMONARY EMBOLISM AND RIGHT HEART STRAIN PATTERN IN COVID-19: AN INCIDENTAL FINDING OR A PERSISTENT PATTERN?
por: Roomi, Sohaib, et al.
Publicado: (2020)

A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines
por: Dardi, Fabio, et al.
Publicado: (2021)

COVID-19-ASSOCIATED COAGULOPATHY AS A PRESENTATION OF CORONAVIRUS DISEASE 2019: A PATIENT PRESENTS WITH A LARGE STROKE, PULMONARY EMBOLISM, AND DVT
por: Ramanathan, Rudra, et al.
Publicado: (2020)

Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy
por: Ghio, Stefano, et al.
Publicado: (2016)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Fukui, Shigefumi, et al.
Publicado: (2016)

Right heart function during simulated altitude in patients with pulmonary arterial hypertension
por: Seccombe, Leigh M, et al.
Publicado: (2017)

Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review
por: Varela, Daniel L, et al.
Publicado: (2018)

Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
por: Han, Yuchi, et al.
Publicado: (2018)

Prognostic relevance of the right ventricular myo-mechanical index (RV-MMI) in patients with precapillary pulmonary hypertension
por: Greiner, Sebastian, et al.
Publicado: (2018)

Mechanisms of ECG signs in chronic obstructive pulmonary disease
por: Larssen, Marte Strømsnes, et al.
Publicado: (2017)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study
por: Gerhardt, Felix, et al.
Publicado: (2017)

CENTRAL AND PERIPHERAL VENOUS THROMBOSIS IN NON-MECHANICALLY VENTILATED SURVIVORS OF COVID-19
por: Nauka, Peter, et al.
Publicado: (2020)

ANTICOAGULATION AND COVID-19: A META-ANALYSIS
por: Ho, Kam Sing, et al.
Publicado: (2020)

PHLEGMASIA CERULEA DOLENS: AN ATYPICAL COVID-19 PRESENTATION
por: Akkari, Riad, et al.
Publicado: (2020)

Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase
por: DiNicolantonio, James J, et al.
Publicado: (2020)

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19
por: Pagnesi, Matteo, et al.
Publicado: (2020)

Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension
por: Chouvarine, Philippe, et al.
Publicado: (2020)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial
por: Russell, Stuart, et al.
Publicado: (2019)

Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry
por: Minatsuki, Shun, et al.
Publicado: (2021)

COVID-19 AS A PRIMARY CAUSE OF PULMONARY ARTERIAL HYPERTENSION
por: RAVAL, ABHIJIT, et al.
Publicado: (2021)

UTILITY OF D-DIMER CUT-OFF POINT WITH VTE IN CRITICALLY ILL PATIENTS WITH COVID-19
por: ZHANG, RAINY, et al.
Publicado: (2021)

THROMOEMBOLIC DISEASE: ONE OF MANY COMMON POST-COVID-19 COMPLICATIONS COMING SOON TO AN EMERGENCY ROOM NEAR YOU
por: BAIRD, ANDREW, et al.
Publicado: (2021)

CASE REPORT OF A COVID-19 INFECTION AND THROMBOEMBOLISM IN A PATIENT WITH ULCERATIVE COLITIS ON TOFACITINIB
por: SOMPALLI, SREEJA, et al.
Publicado: (2021)

SICKLE CELL DISEASE AND COVID-19
por: HANNA, SANDRINE, et al.
Publicado: (2021)

HAS COVID-19 LOST STEAM? A RETROSPECTIVE STUDY ON THE INCIDENCE OF VTE IN PATIENTS WITH COVID-19 AT A LARGE TERTIARY CARE HOSPITAL
por: AMANZAI, ABASIN, et al.
Publicado: (2021)

INCIDENCE AND OUTCOME OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH COVID-19 (SARS-COV-2) INFECTION: A SINGLE CENTER STUDY
por: SAHA, ADITI, et al.
Publicado: (2021)

Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis
por: Slivnick, Jeremy, et al.
Publicado: (2022)

Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland
por: Stubbs, Harrison, et al.
Publicado: (2022)

Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension
por: Suzuki, Sho, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1g02kbem8qgl13qqut3rcpvblf